CN101663031A - 来自长链多不饱和脂肪酸的氧脂素及其制备方法和使用方法 - Google Patents

来自长链多不饱和脂肪酸的氧脂素及其制备方法和使用方法 Download PDF

Info

Publication number
CN101663031A
CN101663031A CN200880012827A CN200880012827A CN101663031A CN 101663031 A CN101663031 A CN 101663031A CN 200880012827 A CN200880012827 A CN 200880012827A CN 200880012827 A CN200880012827 A CN 200880012827A CN 101663031 A CN101663031 A CN 101663031A
Authority
CN
China
Prior art keywords
acid
dpan
epimer
dihydroxy
derivant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880012827A
Other languages
English (en)
Chinese (zh)
Inventor
琳达·阿特伯恩
威廉·巴克利
宾迪·丹吉
詹姆斯·弗拉特
琼·李
达特·文贾莫里
玛丽·范埃尔斯维克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Martek Biosciences Corp
Original Assignee
Martek Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martek Biosciences Corp filed Critical Martek Biosciences Corp
Publication of CN101663031A publication Critical patent/CN101663031A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
CN200880012827A 2007-02-20 2008-02-20 来自长链多不饱和脂肪酸的氧脂素及其制备方法和使用方法 Pending CN101663031A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89070107P 2007-02-20 2007-02-20
US60/890,701 2007-02-20

Publications (1)

Publication Number Publication Date
CN101663031A true CN101663031A (zh) 2010-03-03

Family

ID=39710725

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880012827A Pending CN101663031A (zh) 2007-02-20 2008-02-20 来自长链多不饱和脂肪酸的氧脂素及其制备方法和使用方法

Country Status (5)

Country Link
US (1) US20110190389A1 (https=)
EP (1) EP2120920A4 (https=)
JP (1) JP2010519311A (https=)
CN (1) CN101663031A (https=)
WO (1) WO2008103753A2 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103957888A (zh) * 2011-09-29 2014-07-30 PLx制药公司 用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用
CN108771240A (zh) * 2011-07-21 2018-11-09 帝斯曼知识产权资产管理有限公司 脂肪酸组合物
CN109563517A (zh) * 2016-06-01 2019-04-02 加拿大国家研究委员会 菟葵脂肪酸延伸酶及其在脂肪酸生产中的用途
CN111989399A (zh) * 2018-04-16 2020-11-24 韩国生命工学研究院 多不饱和脂肪酸的多羟基衍生物的制备方法
CN114867476A (zh) * 2019-10-25 2022-08-05 纽希得营养(美国)公司 富集的多不饱和脂肪酸组合物
CN115175892A (zh) * 2020-02-18 2022-10-11 国立大学法人北海道大学 消退素e2的稳定等效物
CN116173001A (zh) * 2012-05-10 2023-05-30 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油
WO2024108603A1 (zh) * 2022-11-25 2024-05-30 中国科学院深圳先进技术研究院 基于粪便代谢物的神经退行性疾病标志物及其应用
CN121027545A (zh) * 2025-10-31 2025-11-28 华中科技大学同济医学院附属协和医院 甲状腺相关眼病的负离子代谢标志物、产品及其应用

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2679224A1 (en) 2007-08-01 2014-01-01 University of Pittsburgh of the Commonwealth System of Higher Education Nitro oleic acid modulation of type II diabetes
CN102083787A (zh) 2008-05-01 2011-06-01 康普雷克萨公司 乙烯基取代的脂肪酸
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2009155439A2 (en) 2008-06-19 2009-12-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
ES2792676T3 (es) * 2008-09-16 2020-11-11 Brigham & Womens Hospital Inc Compuestos del ácido 14-hidroxi-docosahexaenoico
EP2415748A4 (en) 2009-02-20 2013-08-07 Univ Tokyo NEW INFLAMMATORY COMPOUNDS
FR2942964B1 (fr) * 2009-03-16 2012-08-17 Arkopharma Laboratoires Stimulateur metabolique des ppaps a base d'esters d'acides gras libres insatures, composition huileuse et complement alimentaire les contenant
EP2283839A1 (en) * 2009-06-30 2011-02-16 Institut National des Sciences Appliquées de Lyon Polyunsaturated hydroxylated molecule having an eze geometry and its use in therapy
EP2459189A4 (en) * 2009-07-31 2013-01-16 Univ Pittsburgh FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS
WO2011041639A2 (en) 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
EP2744491B1 (en) 2011-08-19 2020-07-29 The University of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
UA114615C2 (uk) 2012-01-06 2017-07-10 Омтера Фармасьютікалз, Інк. Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
EP2809317A4 (en) * 2012-02-03 2015-07-22 Univ Pittsburgh FATTY ACIDS AS ANTI-INFLAMMATORY ACTIVE SUBSTANCES
US9340483B2 (en) * 2012-02-15 2016-05-17 Anida Pharma Inc. Methods of treating amyotrophic lateral sclerosis
HK1206248A1 (en) 2012-05-07 2016-01-08 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
EP3892608B1 (en) * 2013-05-30 2025-07-23 The Brigham and Women's Hospital, Inc. Novel n-3 immunoresolvents: structures and actions
DK3097910T3 (da) * 2014-01-24 2020-07-27 Univ Kyoto Antiinflamatorisk middel indeholdende sjælden fedtsyre
JP6315536B2 (ja) * 2014-01-29 2018-04-25 岩手県 Ｐｐａｒ活性化剤
US11135228B2 (en) * 2014-10-08 2021-10-05 The Brigham And Women's Hospital, Inc. Cysteinyl-proresolving mediators that promote resolution of infection and organ protection
HRP20240082T1 (hr) 2015-07-07 2024-03-29 H. Lundbeck A/S Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
US20180208536A1 (en) * 2015-07-20 2018-07-26 The Brigham And Women's Hospital, Inc. Elucidation of Novel 13-Series Resolvins that Increase with Atorvastatin and Clear Infections
KR20170025977A (ko) * 2015-08-31 2017-03-08 재단법인차세대융합기술연구원 옥시리스 마리나로부터 분리된 신규 화합물
US10653703B2 (en) 2015-09-03 2020-05-19 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same
IL258476B2 (en) 2015-10-02 2023-04-01 Complexa Inc Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
EP3373976B1 (en) 2015-11-10 2024-01-03 Sun Pharmaceutical Industries Limited Topical formulations and uses thereof
FI3801526T3 (fi) 2018-05-25 2024-03-20 Cardurion Pharmaceuticals Inc 6-[(3s,4s)-4-metyyli-1-(pyrimidin-2-yylimetyyli)pyrrolidin-3-yyli]-3-tetrahydropyran-4-yyli-7h-imidatso[1,5-a]pyratsin-8-onin monohydraattimuotoja ja kiteisiä muotoja
EP3843737A4 (en) 2018-08-31 2022-06-01 Imara Inc. PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
CN109161576B (zh) * 2018-09-26 2020-08-07 武汉中科光谷绿色生物技术有限公司 促进枯草芽孢杆菌发酵生产n-乙酰神经氨酸的方法
KR102673270B1 (ko) * 2018-10-15 2024-06-07 (주)아모레퍼시픽 피부장벽 강화용 조성물
KR102704402B1 (ko) 2018-10-24 2024-09-06 (주)아모레퍼시픽 피부장벽 강화용 조성물
KR20220159751A (ko) 2021-05-26 2022-12-05 (주)아모레퍼시픽 미백용 조성물 및 이를 이용한 피부 미백방법
US20250009697A1 (en) * 2021-11-16 2025-01-09 House Foods Group Inc. Composition for increasing amount of food ingested and/or improving anorexia, and composition for activating transient receptor potential ankyrin 1
CN114354785B (zh) * 2021-12-22 2023-06-27 中国农业科学院油料作物研究所 一种基于保留指数结合化学衍生化质谱特征二级碎片的氧脂素综合定性方法
FR3148365A1 (fr) * 2023-05-04 2024-11-08 Pierre Fabre Dermo-Cosmetique Oxylipines dans le traitement de la séborrhée et/ou de l’acné

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866046A (en) * 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
US5102670A (en) * 1990-09-14 1992-04-07 Abraham Nader G Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
US6887901B1 (en) * 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5955496A (en) * 1996-08-13 1999-09-21 The Regents Of The University Of California Dihydroxy-oxy-eicosadienoates
ATE236627T1 (de) * 1996-10-11 2003-04-15 Scarista Ltd Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
US6174695B1 (en) * 1997-08-12 2001-01-16 The Regents Of The University Of California Epoxide hydrolase inhibitor methods
DE19757414A1 (de) * 1997-12-23 1999-07-01 Nutricia Nv Fettmischung
KR100423013B1 (ko) * 1999-03-04 2004-03-12 산토리 가부시키가이샤 도코사펜타엔산 함유물질의 이용
CA2378968A1 (en) * 1999-07-07 2001-01-18 Kyowa Hakko Kogyo Co., Ltd. Process for producing hydroxylated fatty acid and o-lactones
JP4932116B2 (ja) * 2000-02-16 2012-05-16 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アスピリン誘発脂質メディエータ
DE10046541A1 (de) * 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
US7154022B2 (en) * 2000-10-06 2006-12-26 Board Of Trustees Operating Michigan State University Divinyl ether synthase gene, and protein and uses thereof
EP1392623A4 (en) * 2001-05-14 2005-05-04 Martek Biosciences Corp PREPARATION AND USE OF A POLAR LIPID RICH FRACTION CONTAINING HIGHLY UNSATURATED OMEGA-3 AND / OR OMEGA-6 FATTY ACIDS FROM MICROBES, SEEDS OF GENETICALLY MODIFIED PLANTS AND MARINE ORGANISMS
US7527935B2 (en) * 2002-03-19 2009-05-05 Mitsubishi Tanabe Pharma Corporation G-protein coupled receptor having eicosanoid as ligand and gene thereof
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
WO2003084305A2 (en) * 2002-04-01 2003-10-16 University Of Southern California Trihydroxy polyunsaturated eicosanoids
FR2843124B1 (fr) * 2002-08-02 2004-10-15 Goemar Lab Sa Procede de preparation d'acides gras polyinsatures libres et de leurs metabolites d'oxydation
DE60330154D1 (de) * 2002-08-12 2009-12-31 Brigham & Womens Hospital Resolvine: biotemplate zur durchführung therapeutischer anwendungen
US20040166130A1 (en) * 2002-12-23 2004-08-26 L'oreal Lanolin-free cosmetic composition comprising a hydroxylated fatty acid aromatic ester
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
WO2006055965A2 (en) * 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108771240A (zh) * 2011-07-21 2018-11-09 帝斯曼知识产权资产管理有限公司 脂肪酸组合物
CN103957888B (zh) * 2011-09-29 2017-11-21 PLx 制药公司 用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用
CN103957888A (zh) * 2011-09-29 2014-07-30 PLx制药公司 用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用
CN116173001A (zh) * 2012-05-10 2023-05-30 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油
CN109563517A (zh) * 2016-06-01 2019-04-02 加拿大国家研究委员会 菟葵脂肪酸延伸酶及其在脂肪酸生产中的用途
US12291736B2 (en) 2018-04-16 2025-05-06 Korea Research Institute Of Bioscience And Biotechnology Method for producing multi-hydroxy derivatives of polyunsaturated fatty acids
CN111989399A (zh) * 2018-04-16 2020-11-24 韩国生命工学研究院 多不饱和脂肪酸的多羟基衍生物的制备方法
US11987833B2 (en) 2018-04-16 2024-05-21 Korea Research Institute Of Bioscience And Biotechnology Method for producing multi-hydroxy derivatives of polyunsaturated fatty acids
CN114867476A (zh) * 2019-10-25 2022-08-05 纽希得营养(美国)公司 富集的多不饱和脂肪酸组合物
CN115175892A (zh) * 2020-02-18 2022-10-11 国立大学法人北海道大学 消退素e2的稳定等效物
WO2024108603A1 (zh) * 2022-11-25 2024-05-30 中国科学院深圳先进技术研究院 基于粪便代谢物的神经退行性疾病标志物及其应用
CN121027545A (zh) * 2025-10-31 2025-11-28 华中科技大学同济医学院附属协和医院 甲状腺相关眼病的负离子代谢标志物、产品及其应用
CN121027545B (zh) * 2025-10-31 2026-02-03 华中科技大学同济医学院附属协和医院 甲状腺相关眼病的负离子代谢标志物、产品及其应用

Also Published As

Publication number Publication date
JP2010519311A (ja) 2010-06-03
WO2008103753A2 (en) 2008-08-28
US20110190389A1 (en) 2011-08-04
WO2008103753A3 (en) 2008-11-27
EP2120920A4 (en) 2011-06-15
EP2120920A2 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
CN101102988B (zh) 来自长链多不饱和脂肪酸的氧脂素及其制备和使用方法
US7893106B2 (en) Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
CN101663031A (zh) 来自长链多不饱和脂肪酸的氧脂素及其制备方法和使用方法
US20090318394A1 (en) Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
EP1296923B3 (en) Aspirin-triggered lipid mediators
US20090320148A1 (en) Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
AU2001238468A1 (en) Aspirin-triggered lipid mediators
AU2011253846A1 (en) Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US20110027841A1 (en) Method for preparation of oxylipins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100303